Estimaciones de analistas de Wall Street para Niagen Bioscience Inc (NAGE): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 5 |
| Mantener | 0 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 5 |
| Calificación media (1-5) | 1.00 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-03 | $0.01 | ||
| 2026-08-04 | $0.01 | $0.01 | +20.0% |
| 2026-05-06 | $0.07 | $0.06 | +16.7% |
| 2026-03-04 | $0.03 | $0.02 | +50.0% |
| 2025-11-04 | $0.05 | $0.01 | +233.3% |
| 2025-08-06 | $0.04 | $0.02 | +100.0% |
| 2025-05-07 | $0.04 | $0.02 | +100.0% |
| 2025-03-04 | $0.09 | $0.02 | +300.0% |
Ratios de valoración
| Ratio P/E | 15.45 |
| Precio / Valor contable | 2.88 |
| EV / EBITDA | 9.62 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $21.7M | $21.2M | $31.6M | $46.3M | $59.3M | $67.4M | $72.0M | $83.6M | $99.6M | $129.4M |
| Coste de Ventas | $11.3M | $10.7M | $15.5M | $20.5M | $24.0M | $26.0M | $29.3M | $32.8M | $38.0M | $46.2M |
| Beneficio Bruto | $10.4M | $10.5M | $16.1M | $25.8M | $35.3M | $41.5M | $42.8M | $50.8M | $61.6M | $83.2M |
| I+D | $2.5M | $4.0M | $5.5M | $4.4M | $3.4M | $3.8M | $4.8M | $5.0M | $6.0M | $6.3M |
| Generales y Administrativos | $10.8M | $22.1M | $43.7M | $52.5M | $51.7M | $64.7M | $56.6M | $51.4M | $47.8M | $62.6M |
| Gastos Operativos | $13.3M | $26.9M | $49.2M | $57.1M | $55.1M | $68.6M | $61.4M | $56.4M | $53.9M | $68.9M |
| Beneficio Operativo | -$2.9M | -$16.4M | -$33.2M | -$31.3M | -$19.9M | -$27.1M | -$18.6M | -$5.6M | $7.7M | $14.3M |
| EBITDA | -$2.5M | -$15.7M | -$32.3M | -$29.8M | -$18.3M | -$25.4M | -$14.7M | -$3.2M | $10.3M | $19.6M |
| Gastos por Intereses | $371899 | $153000 | $79000 | $847000 | $71000 | $55000 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$3.6M | -$16.5M | -$33.3M | -$32.1M | -$19.9M | -$27.1M | -$16.5M | -$4.9M | $8.9M | $18.2M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $305000 | $810000 |
| Beneficio Neto | -$2.9M | -$11.4M | -$33.3M | -$32.1M | -$19.9M | -$27.1M | -$16.5M | -$4.9M | $8.6M | $17.4M |
| BPA | $-0.08 | $-0.26 | $-0.61 | $-0.56 | $-0.33 | $-0.40 | $-0.24 | $-0.07 | $0.11 | $0.22 |
| BPA Diluido | $-0.08 | $-0.26 | $-0.61 | $-0.56 | $-0.33 | $-0.40 | $-0.24 | $-0.07 | $0.11 | $0.20 |
| Acciones en Circulación (Diluidas) | $37.3M | $44.6M | $55.0M | $57.1M | $61.1M | $67.2M | $69.7M | $75.0M | $79.7M | $85.4M |
Precio
| Precio | $3.00 |
| Capitalización | $239M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: AKBA · CRVS · KALV · KROS · OLMA · PRTA · RGNX
Explorar sector: Healthcare · Biotechnology
Más secciones de NAGE: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones